Has any longevity drug worked yet?
In our AI in drug discovery market deck, you will find everything you need to understand the market
SUMMARY
No. No drug has yet proved that it broadly slows human aging, extends healthy life across several disease categories, and remains safe enough for long-term preventive use.
Some medicines already help people live longer, but that is a narrower achievement. Statins, semaglutide and SGLT2 inhibitors prevent serious disease in defined groups; none has shown that it slows the wider process of aging in generally healthy people.
The field has three different leaders because the evidence does not point to one winner. Rapamycin leads in mammalian aging biology, semaglutide leads in large human outcome data, and SGLT2 inhibitors offer the strongest bridge between animal longevity and established clinical medicine.
Rapamycin’s mouse record is unusually strong, including benefits when treatment starts late in life. Its human evidence is much less dramatic: PEARL found tolerable weekly dosing and a few narrow improvements, but no broad whole-body effect.
Semaglutide has already reduced major cardiovascular events and deaths in a large high-risk population. That makes it more relevant to real human longevity than a favorable biological-age clock, although it still does not prove that aging itself slowed.
VITAL-H matters mainly because of how it is designed. The program is trying to connect biomarkers and geroscience mechanisms with outcomes people actually feel—major illness, disability and survival—rather than declaring victory from a small laboratory change.
Biological-age clocks can move after an intervention, but the observed changes have been small and their clinical meaning is unknown. Until a clock change reliably predicts fewer diseases or deaths, it remains a research measurement, not proof of added healthy years.
The first convincing longevity trial will probably recruit older adults at elevated risk, not perfectly healthy people in middle age. That is the only practical way to collect enough major events within several years rather than waiting decades.
Safety may be the hardest part. A modest reduction in disease can be wiped out by chronic infections, muscle loss, metabolic disruption or other harms that only appear after years of preventive use.
The first real longevity drug will probably look ordinary rather than miraculous. Delaying several major diseases by a few years while preserving physical and cognitive independence would be enough—and would still be one of medicine’s biggest achievements.
This market map, featured in our AI in drug discovery market deck, highlights top companies and startups in the AI in drug discovery market
What would count as a longevity drug actually working?
We should call a longevity drug successful only when people stay healthier for longer and serious side effects do not erase the gain.
The cleanest proof would be a randomized trial in which people receiving the drug live longer than comparable people receiving a placebo. Such a trial could take decades, especially if researchers enrolled healthy adults in middle age.
A practical trial would measure healthspan instead. Researchers could track heart attacks, strokes, cancer, dementia, frailty, loss of independence and death together. A useful drug would need to delay several of these outcomes, rather than winning because it prevented one common but relatively minor event.
Biological-age tests may eventually shorten the process, but they are not reliable substitutes today. A measurement can correlate with mortality without showing that changing the measurement will change mortality. Blood pressure passed that test long ago. Epigenetic clocks have not.
| Claim | Evidence we would need | Current verdict |
|---|---|---|
| Extends human lifespan | Lower all-cause mortality in a large randomized trial | Unproven for any aging-targeted drug |
| Extends healthspan | Fewer major diseases, disabilities and deaths together | Promising trials are starting |
| Slows biological aging | A validated measure that predicts treatment benefit | No accepted surrogate exists |
| Prevents one age-related disease | Better outcomes in a defined patient group | Already proven for many medicines |
If you want more recent data on this point, please see our latest AI in drug discovery market report.
Why does the longevity drug question feel more real now?
The field has finally started building trials that could give us a serious answer.
The clearest recent development is VITAL-H, a program backed by the US Advanced Research Projects Agency for Health. ARPA-H has committed up to $38 million to create a regulatory path for aging treatments and run a phase 3 hybrid trial involving rapamycin, semaglutide and an SGLT2 inhibitor.
Those choices capture the field’s three strongest lines of evidence. Rapamycin has repeatedly extended lifespan in mice. Semaglutide has reduced major cardiovascular events and deaths in a large human trial. SGLT2 inhibitors protect human hearts and kidneys, while one member of the class has also extended male mouse lifespan.
The trial design is the real development, not another promising molecule. Longevity researchers have spent years producing small studies of clocks, inflammatory proteins and physical tests. VITAL-H is meant to connect those measurements with outcomes that patients actually feel: illness, disability and survival.
Its creation also tells us that the central question remains open. Researchers are spending tens of millions of dollars on the trial because none of these drugs has already proved that it slows human aging.
As this chart shows, and as featured in our AI in drug discovery market deck, search interest in AI drug discovery has grown rapidly
Has any drug made healthy humans live longer?
As of now, no randomized trial has shown that an aging-targeted drug makes generally healthy people live longer.
Most human longevity studies have involved dozens or hundreds of participants and lasted several months or a few years. They can detect changes in immune responses, body composition, glucose control or biological-age measurements. They are far too small to establish whether people avoid dementia, disability and death over the following decade.
The timescale creates a brutal research problem. A trial beginning with healthy 55-year-olds could run for 20 years before enough deaths occurred to reveal a clear difference. During that period, participants would change diets, start new medicines, miss doses and benefit from medical advances that did not exist when the trial began.
Researchers are now aiming for earlier endpoints, especially the first occurrence of several major age-related conditions. That approach may prove healthspan extension years before anyone can demonstrate a longer average lifespan.
For now, nobody has completed the human experiment that matters most.
Haven’t ordinary medicines already extended human life?
Yes. Ordinary medicines have extended human life on a massive scale.
Vaccines, antibiotics, blood-pressure treatments and cholesterol-lowering drugs have prevented millions of premature deaths. Large analyses of statin trials found that lowering LDL cholesterol by 1 millimole per litre reduced major vascular events by a little over 20%. Fewer fatal heart attacks and strokes plainly mean more years of life.
Modern heart and kidney drugs have pushed the effect further. SGLT2 inhibitors reduce heart-failure admissions and can lower cardiovascular deaths. Semaglutide has reduced major cardiovascular events among people with obesity or overweight and established cardiovascular disease.
These treatments usually attack a defined risk or disease. Their effects can still be broad, but we cannot assume that preventing heart failure also slows dementia, cancer, immune decline and loss of muscle.
A longevity drug would influence several of those outcomes together, probably by acting on biological processes shared across aging. That standard is much harder to meet.
Still, the distinction may blur. A medicine developed for diabetes could eventually qualify as a healthspan drug if trials showed that it also delayed kidney disease, cardiovascular events, frailty, cognitive decline and death.
This chart, featured in our AI in drug discovery market deck, shows annual venture capital investment in AI drug discovery startups
Which drugs actually make mice live longer?
Rapamycin leads the mouse evidence, although the wider pattern shows why animal results need careful reading.
The US National Institute on Aging’s Interventions Testing Program gives us unusually credible data. Compounds are tested in genetically diverse mice at three independent sites. This reduces the chance that one laboratory, one mouse strain or one unusual colony creates a spectacular result that nobody else can reproduce.
Rapamycin has extended survival in both male and female mice, including animals that started treatment late in life. In the landmark experiment, the age reached by the longest-surviving 10% increased by roughly 9% in males and 14% in females.
Acarbose produced an even larger median-lifespan gain in males, around 22%, with a much smaller female benefit. Canagliflozin increased male median lifespan by 14% and late-life survival by 9%, while female mice gained no extra lifespan.
Those sex differences keep appearing. They suggest that the drugs are interacting with metabolism, hormones and disease patterns in ways that a simple “anti-aging” label hides. They also make translation harder. A treatment that produces a large male-mouse result and no female result is unlikely to become a universal human longevity pill without major refinement.
| Drug | Strong mouse result | Main reason for caution |
|---|---|---|
| Rapamycin | Extended late-life survival by roughly 9% in males and 14% in females | Dose, schedule and health effects vary |
| Acarbose | Increased male median lifespan by around 22% | Female benefit was much smaller |
| Canagliflozin | Increased male median lifespan by 14% | Female lifespan did not increase |
| Metformin | Mixed and relatively modest findings | Evidence is weaker than its reputation suggests |
Has rapamycin worked in people yet?
Rapamycin has produced the clearest human geroscience results so far, but it still has no proof of longer life or broad disease prevention.
The largest recent test was PEARL, a 48-week randomized trial involving 114 adults aged 50 to 85. Participants received a placebo, 5 milligrams of rapamycin each week or 10 milligrams each week.
The main outcome was visceral fat. Rapamycin did not improve it. Most blood measurements also showed no meaningful advantage. Adverse events were similar across the three groups, which supports the idea that intermittent low doses can be tolerated for about a year.
A few narrower results were positive. Women taking 10 milligrams gained lean tissue and reported less pain. People receiving 5 milligrams reported better general health, although some well-being measures also improved in the placebo group. The study found no broader effect across most of the outcomes tested.
We should lower our confidence because every listed author was an employee and shareholder of AgelessRx, the company behind the trial. That does not invalidate the data, but independent replication now matters.
The modest result is useful. Rapamycin looked reasonably safe at these doses and may help specific functions. It did not produce the wide improvement we would expect from a drug that was already slowing whole-body aging.
This chart, featured in our AI in drug discovery market deck, shows how Shrödinger is positioned in AI drug discovery
Did metformin live up to the longevity hype?
Metformin’s reputation is still running far ahead of its human evidence.
The enthusiasm came largely from observational studies. Some found that people with diabetes taking metformin lived longer than people taking other diabetes medicines, and occasionally even longer than groups without diabetes. Those comparisons are difficult to trust because doctors choose treatments according to kidney function, disease severity, weight and overall health.
A randomized longevity trial was supposed to settle the question. The planned TAME study would follow more than 3,000 people aged 65 to 79 across 14 research centres for six years. Researchers would measure the development or progression of heart disease, cancer, dementia and other age-related conditions.
TAME remains a plan rather than a result. The American Federation for Aging Research’s current project page still describes fundraising efforts needed to launch it. After years of headlines presenting TAME as the coming test of human aging, participant recruitment has yet to produce the promised answer.
Smaller experiments have also complicated the story. In one randomized exercise study, older adults taking metformin gained less cardiorespiratory fitness and showed weaker mitochondrial adaptation than participants who exercised without the drug. The result does not cancel metformin’s benefits for diabetes, but it challenges the idea that every metabolic effect associated with the drug is automatically helpful for healthy aging.
Metformin remains cheap, familiar and generally safe for suitable patients. Those qualities make it a practical research candidate. They do not make it a proven longevity treatment.
If you want more recent data on this point, please see our latest AI in drug discovery market report.
Have senolytics worked in humans?
Senolytics have reached human trials, and the first serious results are mostly disappointing.
These drugs are designed to remove senescent cells. Such cells have stopped dividing but remain biologically active, often releasing inflammatory substances that can damage nearby tissue. Removing them improves several age-related conditions in mice.
A randomized phase 2 trial tested dasatinib plus quercetin in 60 postmenopausal women. The treatment failed to improve the main measure of bone resorption after 20 weeks. A bone-formation marker rose by 16% after two and four weeks, but the difference had disappeared by week 20.
Researchers found more encouraging results among women who started with the highest measured burden of senescent cells. That subgroup was exploratory, meaning the trial was not designed or powered to prove the effect. It gives researchers a hypothesis for the next study rather than a treatment result doctors can use.
A recent Nature Aging assessment reached the same broad conclusion: early senolytic trials have produced biological changes, while clear human efficacy remains absent.
The idea may still work in carefully selected patients. Senescent cells differ across tissues, diseases and stages of aging. Killing them everywhere with the same drug may simply be too crude. For now, senolytics remain an interesting mechanism with weak clinical results.
This chart, featured in our AI in drug discovery market deck, shows annual funding in AI drug discovery startups
Is semaglutide already a longevity drug?
Semaglutide currently offers the strongest evidence that a drug can add expected life in a clearly defined high-risk population.
The SELECT trial included 17,604 adults who had cardiovascular disease and were overweight or obese, but did not have diabetes. Participants received semaglutide or a placebo alongside normal medical care.
Major cardiovascular events occurred in 6.5% of the semaglutide group and 8.0% of the placebo group. The relative risk fell by 20%, while the absolute difference was 1.5 percentage points. Roughly 67 similar patients would therefore need treatment over the trial period to prevent one cardiovascular death, heart attack or stroke.
Deaths from any cause also declined. That gives semaglutide a stronger human claim than drugs supported mainly by mouse survival or biological-age measurements. The trial recorded events that directly change people’s lives.
The participants already faced substantial cardiovascular and metabolic risk. Weight loss, lower inflammation, better blood pressure and improved metabolism could explain much of the benefit. We still do not know how semaglutide would affect long-term survival in lean, healthy adults.
Long treatment also has costs. Gastrointestinal side effects are common, some patients lose lean mass alongside fat, and much of the lost weight can return after stopping treatment.
Semaglutide has earned a place in the longevity debate. It has already extended expected survival through better disease prevention in the population studied. Whether it slows aging itself remains unanswered.
If you want more recent data on this point, please see our latest AI in drug discovery market report.
Are SGLT2 inhibitors closer than rapamycin?
SGLT2 inhibitors are closer to proven human survival benefits, while rapamycin remains closer to the traditional biology of aging.
These medicines were developed to lower blood glucose by causing the kidneys to release more glucose into urine. Clinical trials later found benefits that went well beyond glucose control.
In DAPA-HF, 4,744 people with reduced heart function received dapagliflozin or a placebo. The drug reduced worsening heart failure and cardiovascular death, including among participants who did not have diabetes. Other trials found kidney protection and fewer heart-failure admissions across a broader range of patients.
This class also has an unusual connection to animal longevity. Canagliflozin extended male mouse lifespan by 14% in the National Institute on Aging testing program. Female glucose measures improved too, yet their lifespan did not. The mismatch again warns us that metabolic improvements and longer survival are not always the same outcome.
For patients with heart failure or chronic kidney disease, an SGLT2 inhibitor may already increase the chance of living longer. We cannot extend that conclusion to healthy people taking the drug preventively.
Even so, the class offers one of the best bridges between geroscience and normal medicine. The drugs influence metabolism, kidney function, cardiovascular stress and inflammation, and their benefits appear across more than one disease category. That breadth explains their inclusion in VITAL-H.
This chart, featured in our AI in drug discovery market deck, compares the main business model options for AI drug discovery biotech companies
Do biological-age clocks prove anything useful?
Biological-age clocks are useful research tools today, although they still cannot certify that a treatment extends life.
The DO-HEALTH trial offers one of the better examples. Researchers analysed DNA from 777 generally healthy adults over 70 who had been randomly assigned omega-3, vitamin D, exercise or combinations of the three.
Omega-3 moved three DNA-methylation clocks in a favourable direction. The estimated difference after three years amounted to roughly 2.9 to 3.8 months of biological aging. That is a pretty small effect, even before asking what it means clinically.
More recently, a COSMOS analysis examined 958 older adults in a randomized multivitamin trial. Daily multivitamins modestly slowed two epigenetic clocks. The yearly differences were about 0.11 years on one clock and 0.21 years on another. Cocoa extract did not move any of the five clocks tested.
Two separate randomized studies have now shown that these measurements can respond to an intervention. The awkward part is interpretation. We do not know whether a three-month clock difference translates into three more months without cancer, dementia or disability. Different clocks can also give different answers for the same person.
Researchers behind both studies described the effects as small and said their clinical relevance still needed to be established. A recent Nature Medicine review likewise presented clocks as promising tools for risk prediction and research, rather than accepted proof that an intervention slows aging.
A clock result should make us curious, not convinced.
Why do mouse longevity drugs so often disappoint in humans?
Mouse results regularly shrink in humans because the animal experiment is cleaner, shorter and biologically different.
Laboratory mice live in controlled environments. They eat standardized food, rarely miss a dose and avoid smoking, accidents and most infectious exposures. Human lives contain far more variables, each capable of weakening a drug’s measured effect.
Causes of death also differ. Cancer accounts for a large share of deaths in many laboratory mouse colonies. A treatment that delays tumours may produce a striking lifespan increase even if it does little for the mixture of cardiovascular disease, dementia, frailty and chronic illness seen in older humans.
Researchers can also expose mice to doses that would be difficult to tolerate for decades in people. Human studies often use intermittent or lower doses for safety, which may weaken the effect that extended animal lifespan.
Sex adds another complication. Acarbose and canagliflozin produced much larger longevity effects in male mice. Rapamycin’s effects also change according to sex, dose and schedule. Those findings look less like one universal aging switch and more like several biological trade-offs.
Finally, a 20% mouse-lifespan gain does not imply a comparable human gain. Mice and humans age at different speeds and develop different diseases. The animal result tells us that a pathway can influence mammalian survival. It cannot tell us how many human years the same intervention will add.
This chart, featured in our AI in drug discovery market deck, shows revenue breakdown by customer segment in the AI in drug discovery market
Could a longevity drug help one system and harm another?
Yes, and these trade-offs may decide which candidates survive human testing.
Rapamycin illustrates the problem. Lower mTOR activity can reduce excessive cell growth and encourage damaged cellular material to be recycled. The same pathway also supports immune-cell growth, wound healing and normal metabolism.
High or continuous exposure can suppress immunity and disturb glucose control. Intermittent low doses may avoid some of those problems, but the long-term safety of taking them preventively remains unclear.
Metformin may improve glucose regulation while weakening some adaptations to exercise. Semaglutide lowers weight and cardiovascular risk, although nausea, vomiting and loss of lean tissue can matter, especially in older adults already at risk of frailty.
The acceptable risk also changes with the patient. Someone facing organ rejection, cancer or severe heart failure may reasonably accept substantial side effects. A healthy 50-year-old considering 30 years of preventive treatment should demand a much cleaner safety profile.
Even a small yearly increase in infections, muscle loss or metabolic problems could eventually consume a modest longevity gain. A successful drug needs more than an impressive mechanism. It has to remain safe through years of real-world use.
Does a longevity drug need to work in completely healthy people?
The first convincing longevity drug will probably prove itself in older, high-risk adults rather than perfectly healthy volunteers.
Trials need enough illnesses and deaths to measure a difference. Researchers can follow thousands of people at elevated risk for five years and collect meaningful results. The same study among healthy 45-year-olds might need decades.
Starting with higher-risk adults is also easier to justify. Their potential benefit is larger, and the diseases researchers hope to prevent are already close enough to observe.
Semaglutide followed this route through people with cardiovascular disease and excess weight. SGLT2 inhibitors established their value in diabetes, heart failure and kidney disease. A future trial could then ask whether their effects extend across several aging-related conditions.
The endpoint matters more than whether every participant begins in perfect health. A treatment that delays cardiovascular disease, cancer, dementia, frailty and death together would qualify as a healthspan drug. Scientists would still need to investigate its mechanism, but patients would already be gaining healthier years.
Researchers must report each part of the combined endpoint separately. A trial should not declare success because one common hospital event declined while mortality, cognition and independent living remained unchanged.
Broad, clinically meaningful disease prevention would be enough to say that a longevity drug works. Proving that one universal rate of aging slowed is a harder and less useful requirement.
This chart, featured in our AI in drug discovery market deck, shows how AI drug discovery platform technology has evolved over time
Which longevity candidate looks strongest right now?
The field has three different leaders: rapamycin for aging biology, semaglutide for human outcomes and SGLT2 inhibitors for translation between the two.
Rapamycin has the most convincing mammalian longevity record. It extends mouse lifespan across several experiments and still works when treatment starts late. PEARL added useful human safety data, but its clinical benefits were narrow.
Semaglutide has the best large-scale human evidence. SELECT recorded fewer major cardiovascular events and fewer deaths among more than 17,000 participants. Its weakness is scope: the trial involved a high-risk population and did not establish slower aging across the body.
SGLT2 inhibitors sit between them. They protect human hearts and kidneys, work in some people without diabetes and have a direct mouse-longevity result. Their evidence is broader than one disease, although preventive use in healthy adults remains untested.
Metformin is easier and cheaper to study, but its reputation rests heavily on observational research. Senolytics target aging more directly, yet human trials have produced little clinical benefit so far.
| Candidate | Best evidence today | Biggest missing piece | Current judgment |
|---|---|---|---|
| Rapamycin | Repeated mouse lifespan extension and early human safety data | Large human disease or survival benefit | Strongest geroscience candidate |
| Semaglutide | Fewer cardiovascular events and deaths in a large human trial | Evidence in healthier populations and across more diseases | Strongest human outcome evidence |
| SGLT2 inhibitors | Human heart and kidney protection plus male mouse longevity | General human healthspan benefit | Best translational bridge |
| Metformin | Long clinical history, low cost and plausible biology | A completed randomized healthspan trial | Hype exceeds the evidence |
| Senolytics | Strong mouse mechanisms and measurable biological activity | Clear and repeated human clinical benefit | Promising idea, weak results |
If you want more recent data on this point, please see our latest AI in drug discovery market report.
What result would finally settle the question?
A large randomized trial must show fewer major diseases, less disability and lower mortality without an offsetting safety cost.
The study should include several thousand older adults who are still living independently but have enough risk to produce measurable outcomes within a reasonable period.
Researchers would follow cardiovascular disease, cancer, dementia, persistent frailty, disability and death. A combined endpoint could make the trial manageable, provided the results also showed what happened to each individual condition.
Physical and cognitive function deserve equal attention. Keeping someone alive while increasing weakness, dependence or cognitive impairment would be a poor version of longevity.
Safety must also be measured over years. Short trials can miss gradual muscle loss, metabolic changes, recurrent infections and rare complications that become important when millions of healthy people take a drug.
Biological-age clocks and blood biomarkers could help explain the result. They may later allow shorter and cheaper trials once researchers know which changes predict real clinical benefits. Until then, the illnesses, disabilities and deaths must carry the verdict.
In our AI in drug discovery market deck, we identify pain points entrepreneurs should prioritize
Has any longevity drug worked yet?
Partly, but the first proven human longevity drug has not arrived.
Rapamycin works well enough in mice to justify serious human trials. Semaglutide and SGLT2 inhibitors already prevent deaths and major disease in specific high-risk populations. Senolytics can change biological processes without yet producing convincing clinical benefits. Omega-3 and multivitamins have moved aging clocks slightly, with no proof that the clock changes add healthy years.
No candidate has connected the complete chain in humans: altering aging biology, delaying several unrelated diseases, preserving physical and cognitive independence, reducing mortality and remaining safe enough for long-term preventive use.
So the answer is partial. Longevity drugs have worked in animals and in narrower areas of human medicine. The claim that a drug already slows human aging is still premature.
The first real success will probably look less dramatic than the industry’s marketing. It may delay several diseases by a few years rather than make people live to 150. That would still rank among medicine’s largest achievements.
For now, rapamycin remains the strongest scientific bet, semaglutide has the strongest human survival evidence, and SGLT2 inhibitors offer the most credible bridge between the two. None has earned the title of proven human longevity drug.
If you want more recent data on this point, please see our latest AI in drug discovery market report.
OUR METHODOLOGY
This analysis tests what evidence would be strong enough to say that a longevity drug works in humans. We separate lifespan, healthspan, disease prevention, biological-age measurements, safety and real-world clinical usefulness rather than treating them as interchangeable claims.
We give the most weight to large randomized human trials that measure deaths, major disease, disability, physical function or cognitive decline. Government research programs, registered clinical trials and replicated multi-site animal studies come next. Observational studies, small biomarker trials and biological mechanisms are treated as supporting evidence, not final proof.
For human longevity, the core standard is broad clinical benefit. A drug would need to delay several important age-related outcomes together and preserve independence without creating a long-term safety cost that cancels the gain.
For animal evidence, we rely heavily on the National Institute on Aging’s Interventions Testing Program because it tests compounds in genetically diverse mice across three independent sites. That makes its findings more useful than a lifespan result from one laboratory or one unusually responsive mouse strain.
For human outcome evidence, we use major randomized trials including SELECT for semaglutide and DAPA-HF for dapagliflozin. These trials establish meaningful benefits in defined high-risk populations, but we do not automatically interpret disease prevention in those groups as proof that the underlying rate of aging slowed.
We treat biological-age clocks as research tools rather than accepted surrogate endpoints. The DO-HEALTH and COSMOS analyses show that randomized interventions can move some epigenetic clocks, but the changes remain small and have not yet been linked to a known increase in healthy lifespan.
We also account for conflicts and evidence quality. PEARL adds useful information on intermittent rapamycin dosing, but its company-linked authorship lowers confidence until the findings are independently replicated. TAME is treated as a proposed trial rather than completed evidence.
Key sources include: ARPA-H’s VITAL-H program, the National Institute on Aging’s Interventions Testing Program, the PEARL rapamycin trial record, AFAR’s TAME project page, the SELECT semaglutide trial, the DAPA-HF trial, the DO-HEALTH biological-aging analysis, the COSMOS trial publication, and reviews and trial records from Nature Aging, Nature Medicine and ClinicalTrials.gov.
This chart, featured in our AI in drug discovery market deck, shows revenue breakdown by region across Europe, Asia, North America, Africa, and South America in the AI in drug discovery market
Related blog posts
- Who is closest to a real anti-aging drug today?
- Has AI discovered a real drug?
- Who is closest to reversing aging?
- Which startup looks most promising in reversing cellular aging?
